No products in the cart.
Pre-made Demcizumab benchmark antibody ( Whole mAb, anti-DLL4 therapeutic antibody, Anti-AOS6/delta4/hdelta2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-137
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Demcizumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Demcizumab /d?m?s?z?m?b/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.
| Products Name (INN Index) | Pre-Made Demcizumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody |
|---|---|
| INN Name | Demcizumab |
| Target | DLL4 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Celgene Corporation,OncoMed Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Colorectal cancer,Fallopian tube cancer,Non-small cell lung cancer,Ovarian cancer,Pancreatic cancer,Peritoneal cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | DLL4 |
| Package |
Previous slide
Next slide
